Abstract
Platelet hyperactivity plays an important role in the pathogenesis of cardio-vascular diseases. In patients with stable angina pectoris, we have recently demonstrated that nitroglycerin suppressed the increased platelet aggregability. The anti-aggregating effect of NTG and other nitrovasodilators is mediated by platelet guanylate cyclase, which generates cyclic GMP (cGMP) in response to nitric oxide (NO) liberated from the nitrovasodilator molecule. In the current study we utilised a more “direct” NO donor, sodium nitroprusside (SNP), to examine reversal of ADP-induced platelet aggregation in comparison with intraplatelet cGMP elevation in platelets from normal subjects (n = 22) and patients with stable angina pectoris (n = 23).
Concentrations of SNP associated with 50% reversal of aggregation were 2.7 ± 0.4 × 10−7 mol/L with normal subjects and 4.5 ± 0.5 × 10−6 mol/L with patients (P < 0.01). SNP produced a concentration-dependent elevation of intraplatelet cGMP content: with 10−4 mol/L SNP this was 17-fold for normals and 5-fold for patients (P < 0.01). An increase in cAMP content was seen only with 10−4 mol/L SNP, and was 157 ± 11% of baseline in platelets from normal subjects and 138 ± 14% in patients. There was a strong interrelationship between cGMP-stimulating and anti-aggregating effects of SNP. The decrease in cGMP responsiveness to SNP was not related to a dysfunction of platelet guanylate cyclase; neither basal nor SNP-stimulated activity of the enzyme varied significantly between normal subjects and patients. Lipophilic derivatives of cGMP (db-cGMP) and cAMP (db-cAMP) caused reversal of aggregation; there was a nonsignificant trend towards decreased responsiveness of platelets from patients to both db-cGMP and db-cAMP.
The observed decrease in responsiveness of platelets from angina patients to anti-aggregating effects of the exogenous NO donor, SNP, can therefore be attributed to suppressed cGMP accumulation. These results imply reduced platelet sensitivity to endogenous NO (endothelium-derived relaxing factor); this might contribute to platelet hyperaggregability observed in angina pectoris.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Young A (1994) Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol 24:555–566
Bashour TT, Myler RK, Andreae GE, Stertzer SH, Clark DA, Ryan CJM (1988) Current concepts in unstable myocardial ischemia. Am Heart J 115:849–861
Body SC (1996) Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 27:S13-S25
Chirkov YY, Belushkina NN, Tyshchuk IA, Severina IS, Horowitz JD (1991) Increase in reactivity of human platelet guanylate cyclase during aggregation potentiates the disaggregating capacity of sodium nitroprusside. Clin Exp Pharmacol Physiol 18:517–524
Chirkov YY, Naujalis J, Barber S, Sage RE, Gove DW, Brealy JK, Horowitz JD (1992) Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol 70:802–806
Chirkov YY, Naujalis JI, Sage RE, Horowitz JD (1993a) Antiplatelet effect of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol 21:384–389
Chirkov YY, Gee DJ, Naujalis J, Sage RE, Horowitz JD (1993b) Reversal of human platelet aggregation by S-nitrosothiols, nitroglycerine and nitroglycerine/N-acetylcysteine. Pharmacol Commun 3:97–105
Chirkov YY, Chirkova LP, Sage RE, Horowitz JD (1995) Impaired responsiveness of platelets from patients with stable angina pectoris to anti-aggregating and cAMP-elevating effects of prostaglandin E1. J Cardiovasc Pharmacol 25:961–966
Chirkov YY, Horowitz JD (1995) N-acetylcysteine potentiates nitroglycerine-induced reversal of platelet aggregation. Aust NZ J Med 25:643
Diodati JG, Cannon RO, Epstein SE, Quyyumi AA (1992) Platelet hyper-aggregability across the coronary bed in response to rapid atrial pacing in patients with stable coronary artery disease. Circulation 86:1186–1193
Diodati JG, Cannon RO, Hussain N, Quyyumi AA (1995) Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am J Cardiol 75:443–448
Frishman WH, Weksler B, Christodoulou JP, Smithen C, Killip T (1974) Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 50:887–896
Gerzer R, Drummer C, Karrenbrock B, Heim J-M (1989) Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo. J Cardiovasc Pharmacol 14: S115-S119
Kinlough-Rathbone RL, Packham MA, Mustard JF (1983) Platelet aggregation. In: Harker LA, Zimmerman TS (eds) Measurements of platelet function. Churchill Livingstone, Edinburgh London Melbourne New York, pp 64–91
Loscalzo J, Welch G (1995) Nitric oxide and its role in the cardiovascular system. Progr Cardiovasc Dis 38:87–104
Maurice DH, Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671–681
Moncada S, Higgs EA (1991) Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 21: 361–374
Noack E, Feelisch M (1991) Molecular mechanisms of nitrovasodilator bioactivation. Basic Res Cardiol 86 [Suppl 2]:37–50
Salvemini D, Botting R (1993) Modulation of platelet function by free radicals and free-radical scavengers. Trends Pharm Sci 14:36–42
Terres W, Weber K, Kupper W, Bleifeld W (1991) Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach. Thromb Res 62:649–661
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chirkov, Y.Y., Chirkova, L.P. & Horowitz, J.D. Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn-Schmiedeberg's Arch Pharmacol 354, 520–525 (1996). https://doi.org/10.1007/BF00168445
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168445